Brandon Chen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (48)
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints. See related Spotlight by Nasrollahi and Davar, p. 383.
Year:
2024
Year:
2024
Immunofluorescence staining of PD-L1+ CD68 myeloid cells in the bone biopsies. A. RNAscope staining of DAPI (cyan), CD68 (orange), PD-L1 (magenta), Tim3 (green), TIGIT (white) and overlay of bone marrow metastasis. CD68+ cells that co-express PD-L1 are indicated with arrow. Tim3+ cells are indicated with pointer. Scale bar, 20 μm. B. Scatterplot of PDL1+ CD68+ cell frequencies of tissue imaging data and PDL1+ CD14+ CD3-CD19- myeloid cell frequencies of CyTOF data from blood samples taken at the same timepoint (baseline, n=10 patients). R2 value is based on Pearson correlation. C. Scatterplot of TIM3+ CD68- cell frequencies on tissue imaging and TIM3+ CD3+ T cell frequencies of CyTOF data from blood samples taken at the same timepoint (baseline, n=10 patients). R2 value is based on Pearson correlation.
Year:
2024
Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing with “[” representing cycle 3 day 28 and “]” representing cycle 4 day 1 when the interval between these was greater than 28 days. Patients could resume radium treatment at radiographic progression by PCWG2 criteria (“△”) if there were no new visceral metastases, but two patients (bars 7 and 13 below) resumed without confirmed radiographic progression.
Year:
2024
Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ proportion above vs. below median. C. baseline CD8+ / CD4+FoxP3+ (Treg) ratio above vs. below median. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.
Year:
2024
Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing with “[” representing cycle 3 day 28 and “]” representing cycle 4 day 1 when the interval between these was greater than 28 days. Patients could resume radium treatment at radiographic progression by PCWG2 criteria (“△”) if there were no new visceral metastases, but two patients (bars 7 and 13 below) resumed without confirmed radiographic progression.
Year:
2024
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P) activity. In a randomized phase II study, we assessed the effect of R223+P compared with R223 on tumor immune infiltration, safety, and clinical outcomes in patients with mCRPC. The primary endpoint was differences in CD4 + and CD8 + T-cell infiltrate in 8-week versus baseline bone metastasis biopsies; secondary endpoints were safety, radiographic progression-free survival (rPFS), and overall survival (OS). Of the 42 treated patients (29 R223+P, 13 R223), 18 R223+P and 8 R223 patients had evaluable paired tumor biopsies. Median fold-change of CD4 + T cells was −0.7 (range: −9.3 to 4.7) with R223+P and 0.1 (−11.1 to 3.7) with R223 ( P = 0.66); for CD8 + T cells, median fold-change was −0.6 (−7.4 to 5.3) with R223+P and −1.3 (−3.1 to 4.8) with R223 ( P = 0.66). Median rPFS and OS was 6.1 (95% confidence interval: 2.7–11.0) and 16.9 months [12.7–not reached (NR)], respectively, with R223+P and 5.7 (2.6–NR) and 16.0 (9.0–NR), respectively, with R223. Although R223+P was well tolerated with no unexpected toxicity, the combination did not improve efficacy. High-dimensional flow cytometry demonstrated minimal immune modulation with R223, whereas R223+P induced CTLA-4 expression on circulating CD4 + T cells. Clinical responders possessed lower circulating frequencies of Ki67 + T and myeloid cells at baseline and higher circulating frequencies of TIM-3 + T and myeloid cells by week 9. Although R223+P did not induce T-cell infiltration into the tumor microenvironment, exhaustion of induced peripheral T-cell immune responses may dampen the combination's clinical activity.
Year:
2024
Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. CD4+FoxP3- (effector) proportion increase vs. decrease from baseline to 8-week biopsy. B. CD8+ increase vs. decrease. C. CD8+ / CD4+FoxP3+ (Treg) ratio increase vs. decrease. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.
Year:
2024
Immune cell functional states differ in clinical responders compared to non-responders. (A) Heat maps summarizing log2 fold changes resulting from statistical scaffold analysis of functional markers 4-1BB, CD44, CTLA-4, GITR, HLA-DR, ICOS, Ki-67, OX40, PD-1, PD-L1, PD-L2, TIGIT, TIM3 and VISTA are shown for Week 1, Week 5, and Week 9, when comparing responders to non-responders as defined by rPFS.
Year:
2024
Immune cell functional states differ in clinical responders compared to non-responders. (A) Heat maps summarizing log2 fold changes resulting from statistical scaffold analysis of functional markers 4-1BB, CD44, CTLA-4, GITR, HLA-DR, ICOS, Ki-67, OX40, PD-1, PD-L1, PD-L2, TIGIT, TIM3 and VISTA are shown for Week 1, Week 5, and Week 9, when comparing responders to non-responders as defined by rPFS.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (13)
Lucia Kwak
Johns Hopkins University
Eliezer Van Allen
Professor
Harvard University
Li Zhang
Professor
UCSF
Bridget P. Keenan
University of California
Christopher J. Sweeney
University of Adelaide
Eric J. Small
University of California, San Francisco
Franklin W. Huang
-
Lawrence Fong
Fred Hutch Cancer Center
David Yang
Dana-Farber Cancer Institute
Atish Choudhury
Dana-Farber Cancer Institute
Rahul Aggarwal
University of California
Terence Friedlander
University of California, San Francisco
Bradley McGregor
Dana-Farber Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.